mycophenolic-acid and Anemia--Hypochromic

mycophenolic-acid has been researched along with Anemia--Hypochromic* in 1 studies

Trials

1 trial(s) available for mycophenolic-acid and Anemia--Hypochromic

ArticleYear
Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2004, Volume: 43, Issue:6

    Oral administration of ferrous-sulfate was reported to decrease intestinal absorption of mycophenolate mofetil (MMF) in healthy Japanese individuals by 90%.. We examined the effect of a single oral dose of ferrous sulfate on steady-state mycophenolic acid pharmacokinetics in 10 iron-deficient (hypochromic red blood cells >2.5%), Caucasian, long-term kidney graft recipients using a randomized, open-label, crossover design. On days A and B, MMF (1,000 mg) was given orally at 8:00 am. On day C, MMF and ferrous sulfate (105 mg) were coadministered at 8:00 am. On day D, MMF was given at 8:00 am and ferrous sulfate was given orally 4 hours later.. The interindividual variability of the 12-hour area under the plasma mycophenolic acid concentration versus time curves (AUC(0-12)) under control conditions was small (89.5 +/- 27.8 and 87.6 +/- 39.1 mg x h/L, respectively). Concomitant or subsequent administration of MMF and ferrous sulfate did not affect the bioavailabilty of MMF (AUC(0-12), 91.9 +/- 30.4 mg x h/L and 96.0 +/- 31.7 mg x h/L).. Oral therapy of iron deficiency using ferrous sulfate in long-term kidney graft recipients does not impede intestinal absorption of MMF; hence, exposure to this immunosuppressive agent is not reduced.

    Topics: Administration, Oral; Anemia, Hypochromic; Anemia, Iron-Deficiency; Area Under Curve; Biological Availability; Cross-Over Studies; Drug Interactions; Erythrocytes; Female; Ferrous Compounds; Humans; Intestinal Absorption; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Time; Time Factors

2004